Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
February 20, Tuesday 2018 3:03 PM       

       HEADLINES: Youth commits suicide by jumping into backwater                                              No intention to reveal name of minister who kissed my palm: Former PRD official                                              SC to consider Priya’s plea on Wednesday                                              Plea seeking SIT probe into PNB scam likely to be mentioned before CJI bench                                              Manoj Kharat's father says 'PNB framed my son'                                              Regime forces kill 77 in Syria                                              Ashwin, Gibbs involved in Twitter spat                                              Cricket can melt ice between India and Pak: Afridi                                              ‘Out-of-favour’ Usman Qadir plan to represent Australia in 2020 World T20                                              Kaumudi Facebook
       SCI&TECH Next Article: Threat of asteroid impact looming over Earth: experts  
       New drug to treat blood cancer developed
 
         Posted on :19:38:19 Jun 10, 2017
   
A A
       Last edited on:19:38:19 Jun 10, 2017
         Tags: New drug, blood cancer
 
NEW YORK: A new drug for blood cancer that may provide better treatment alone or combined with chemotherapy has been developed by a team led by an Indian-origin scientist.
 
Acute lymphoblastic leukemia or ALL can affect both children and adults.
 
Scientists have found up to 30 per cent of adult ALL patients have what is called a Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. The ALL cancer cells containing the Philadelphia chromosome are addicted to repairing DNA.
 
"Repairing DNA may sound like a good thing when you are talking about healthy cells. But in this case it is a bad thing. When you treat these leukemia cells with chemotherapy, you want DNA damage to accumulate so the cancer cells will die," said Srividya Bhaskara, a post doctoral at University of Utah in the US.
 
"However, because the Philadelphia chromosome continually causes repair, these cells do not retain enough DNA damage to die. Essentially they resist any kind of drug you use on them. So we had to find a new way to overcome this DNA repair addiction," she said.
 
Researchers found that the Philadelphia chromosome promotes repair through numerous proteins. But putting together a cocktail of drugs to inhibit them all would likely be too toxic and affect normal cells.
 
Bhaskara focused on two specific proteins she found were directly involved in DNA repair, called histone deacetylases (HDAC) 1 and 2. She then collaborated with a company to make a drug that inhibits HDAC1,2 activity.
 
After a comprehensive analysis of how the drug worked, Bhaskara tested the HDAC1,2 inhibitor in patient samples and mice and saw encouraging results, either alone or in combination with a chemotherapy drug called doxorubicin.
 
Doxorubicin is one of the components of the chemotherapy cocktail regimen currently used for Philadelphia chromosome-positive ALL patients.
 
Researchers found that the drugs broke down the central hub of DNA repair, and the HDAC1,2 inhibitor actually reduced different repair protein functions.
 
"The treated mice did not get sick from the drug, and we did not see any apparent toxic side-effects in them. And when the drug was combined with a low concentration of doxorubicin, it had additional therapeutic benefits," Bhaskara said.
 
"We actually show in the patient-derived mouse models that using the combination of drugs, or HDAC1,2 inhibitor alone, is sufficient to decrease the leukemia load," she said.
 
Leukemia is a white blood cell disease where the body produces too many white and not enough red blood cells.
 
When the mice in this study were treated with the HDAC1,2 inhibitor or the HDAC1,2/doxorubicin combination, their bone marrow started turning from pale to red, indicating the white blood cells were being replaced with red blood cells, researchers said.
 
"We completely nailed down how the HDAC1,2 inhibitor affects DNA repair. This is so important, not just for this cancer, but any cancer that is repair-addicted. We know there is a specific type of lymphoma that is also repair-addicted," Bhaskara said.
 
The study was published in the journal Leukemia.
A A
       SCI&TECH
Next Article: Threat of asteroid impact looming over Earth: experts
 
 
SCI&TECH HEADLINES
Ensuring sexual, reproductive health for overall well-being  
WeChat gets popular in Bhutan: report  
Celebrate love this Valentine's Day with Google Pixel 2  
This drug could reverse alcohol's damaging effects on brain  
Scientists discover enormous reserves of mercury in permafrost  
Google Assistant helps you set music alarms  
What is epilepsy?  
Here're some ways to keep dementia at bay  
What are memories made of?  
Second-hand plastic toys could harm your kid  
Working before and after stroke is good for brain health  
ixigo introduces India's first augmented reality feature for Train Passengers  
Super blue moon on Jan. 31 will mark last of trilogy  
Now, a blood test that can screen eight cancer types  
Secret of longevity protein revealed!  
Absence of this gene can give men deadly cancer  
Soon, you can demote group admins on WhatsApp  
Regular yoga can slow down ageing of brain: Study  
What are haemorrhoids (piles) and what causes them?  
WhatsApp facilitates quick switch from voice to video call  
The Thin and Light Lenovo Ideapad 720s shines at Digit Zero 1 Awards  
Frequent heartburns up cancer risk in older adults  
Blueberry vinegar can help fight dementia  
iPhones with older batteries will take a hit in performance: Apple  
Eighth planet found in faraway solar system, matching ours  
 
Do you think the arrested persons in Shuhaib murder case are real culprits?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy